| Safety analysis population (n = 2602) | Efficacy analysis population (n = 1629) | |
| Number of patients | 2602 | 1629 |
| Number of patients with adverse drug reactions | 14 | 8 |
| Number of cases of adverse drug reactions | 15 | 9 |
| Incidence (%) of adverse drug reactions | 0.54% | 0.49% |
| Types of adverse drug reactions | Incidence of serious adverse drug reactions by type number of patients (%) | |
| Metabolism and nutrition disorders | 9 (0.35) | 4 (0.25) |
| Inadequate glycaemic control | 1 (0.04) | 0 (0.00) |
| Hypoglycaemia | 8 (0.31) | 4 (0.25) |
| Nervous system disorders | 1 (0.04) | 1 (0.06) |
| Hypoglycaemic seizure | 1 (0.04) | 1 (0.06) |
| Hypoglycaemic unconsciousness | 1 (0.04) | 1 (0.06) |
| Eye disorders | 1 (0.04) | 1 (0.06) |
| Diabetic retinopathy | 1 (0.04) | 1 (0.06) |
| General disorders and administration site conditions | 1 (0.04) | 1 (0.06) |
| Death* | 1 (0.04) | 1 (0.06) |
| Laboratory tests | 2 (0.08) | 1 (0.06) |
| Blood glucose level increased | 2 (0.08) | 1 (0.06) |